SCHEMBL3844820

SCHEMBL3844820

Cc1ccccc1Nc1nc(-c2ccc3[nH]c(NC(=O)c4cccs4)nc3c2)cc(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
STK33 Q9BYT3 7/20 0.47
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
POLB P06746 4/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
ITK Q08881 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
THRB P10828 1/20 0.41
MAPT P10636 4/20 0.40
APAF1 O14727 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
PPARG P37231 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14513964 0.93 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3847287 0.90 NPC1 (0.53) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3903906 0.90 SMN1; SMN2 (0.53) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL5633833 0.89 NPC1 (0.51) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3842188 0.88 KDM4E (0.57) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3852588 0.87 SMN1; SMN2 (0.48) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3843297 0.85 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3848441 0.85 KDM4E (0.49) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3844543 0.84 SMN1; SMN2 (0.54) KDM4ENPC1RAB9ASMN1; SMN2STK33
SCHEMBL3843039 0.84 KDM4E (0.52) KDM4ENPC1RAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713793-A4 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-09-02 EP claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US claimed
EP-1713793-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS Smithkline Beecham Corporation (US) 2006-10-25 EP claimed
WO-2005076854-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HIPK3, HIPK1, HIPK2 KDM4E 1975/4885NPC1 3400/4885RAB9A 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.